Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$0.94 - $1.23 $4,634 - $6,063
4,930 Added 20.45%
29,041 $27,000
Q2 2023

Aug 11, 2023

SELL
$1.1 - $1.54 $22,333 - $31,266
-20,303 Reduced 45.71%
24,111 $29,000
Q1 2023

May 12, 2023

BUY
$1.19 - $2.09 $8,708 - $15,294
7,318 Added 19.73%
44,414 $55,000
Q4 2022

Feb 13, 2023

BUY
$1.67 - $2.35 $4,203 - $5,914
2,517 Added 7.28%
37,096 $68,000
Q3 2022

Nov 14, 2022

BUY
$1.81 - $2.76 $4,934 - $7,523
2,726 Added 8.56%
34,579 $67,000
Q2 2022

Aug 15, 2022

SELL
$1.34 - $5.34 $56 - $224
-42 Reduced 0.13%
31,853 $66,000
Q1 2022

May 16, 2022

SELL
$4.58 - $6.8 $1.46 Million - $2.17 Million
-319,408 Reduced 90.92%
31,895 $147,000
Q4 2021

Feb 14, 2022

BUY
$5.23 - $7.18 $1.63 Million - $2.24 Million
311,361 Added 779.53%
351,303 $2.26 Million
Q3 2021

Nov 15, 2021

BUY
$5.94 - $8.75 $45,720 - $67,348
7,697 Added 23.87%
39,942 $247,000
Q2 2021

Aug 17, 2021

SELL
$7.54 - $9.79 $2.53 Million - $3.29 Million
-335,630 Reduced 91.23%
32,245 $257,000
Q1 2021

May 17, 2021

BUY
$4.76 - $11.25 $363,287 - $858,611
76,321 Added 26.18%
367,875 $3.55 Million
Q4 2020

Feb 16, 2021

BUY
$2.43 - $5.42 $708,476 - $1.58 Million
291,554 New
291,554 $1.41 Million
Q1 2020

May 15, 2020

SELL
$1.27 - $2.33 $129,973 - $238,454
-102,341 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$1.3 - $2.72 $8,768 - $18,346
-6,745 Reduced 6.18%
102,341 $208,000
Q3 2019

Nov 14, 2019

SELL
$1.93 - $4.21 $8,221 - $17,934
-4,260 Reduced 3.76%
109,086 $256,000
Q2 2019

Aug 14, 2019

SELL
$2.05 - $4.32 $126,232 - $266,012
-61,577 Reduced 35.2%
113,346 $490,000
Q1 2019

May 15, 2019

BUY
$1.79 - $3.12 $60,591 - $105,612
33,850 Added 23.99%
174,923 $367,000
Q4 2018

Feb 14, 2019

BUY
$2.24 - $3.9 $316,003 - $550,184
141,073 New
141,073 $363,000

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $85M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.